Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested

New draft Q&A and three final guidances from FDA offer pros and cons for sponsors of biosimilar applications.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America